Taiho Oncology, Inc.

Quick facts

Marketed products

• CPT-11 · Oncology
• Lonsurf · Oncology
  Lonsurf works by inhibiting the enzyme thymidine phosphorylase, which is involved in the breakdown of certain cancer medications.

Phase 3 pipeline

• ASTX727 · Oncology
  ASTX727 is a fixed-dose combination of decitabine and cedazuridine that inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes in myelodysplastic syndrome.
• TAS-120 · Oncology
  TAS-120 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to suppress tumor cell growth.
• TAS6417 · Oncology
  TAS6417 is a small-molecule inhibitor of TGF-β signaling that blocks the TGF-β receptor pathway to reduce immunosuppression in the tumor microenvironment.

Phase 2 pipeline

• futibatinib, fulvestrant
• TAS-114
• Transporter Cocktail

Phase 1 pipeline

• ASTX727 LD
• ASTX727 SD
• TAS-102 tablets
• TAS3681
• Tolinapant · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Taiho Oncology, Inc. portfolio CI brief
• Taiho Oncology, Inc. pipeline updates RSS